Liraglutide, a GLP-1 receptor agonist (GLP-1RA), was shown to reduce serum total cholesterol, LDL-C, high-density lipoprotein cholesterol (HDL-C), and TG levels by decreasing hepatic LDLR and PCSK9 expression in db/db mice, but not in wild-type mice [16]
This is because exposure to heat or direct sunlight can reduce the efficacy of the bacteriostatic preservative
And with newer GLP-1s and oral options like oral semaglutide, there is more flexibility than before
Yes, they are often recommended together for enhanced antioxidant benefits
Results: The XB model showed superior performance compared to both RF and Cox regression in predicting left atrial enlargement (LAE) (PR-AUC = 0.71, specificity = 75%, sensitivity = 64%), left ventricular (LV) akinesia (PR-AUC = 0.44, specificity = 96%, sensitivity = 54%), and aortic plaques (PR-AUC = 0.29, specificity = 27%, sensitivity = 79%)